Health
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerabilityAt the maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse eventsThe data support further development of petrelintide in chronic weight management as monotherapy and its tolerability profile also confirms its value as a combination partner Basel, 05 March 2026 - Roche (
About this update from Roche Holding Ltd
[{"type":"image","alt":"F. Hoffmann-La Roche Ltd","displaySize":"","headline":null,"caption":"F. Hoffmann-La Roche Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":198,"url":"https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TdqKHuoAMRswPfW7YQ22wg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2","width":300,"height":198}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerability","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"At the maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"The data support further development of petrelintide in chronic weight management as monotherapy and its tolerability profile also confirms its value as a combination partner","length":174,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":472,"olType":false},{"type":"text","content":"Basel, 05 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo in 493 people living with overweight and obesity (mean BMI of 37 kg/m²) in a gender-balanced trial population. The study met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (escalated every fourth week ) resulted in statistically significant and clinically meaningful weight loss from baseline after 28 weeks in all five treatment arms compared to placebo.","length":589,"tagName":"p"},{"type":"text","content":"The weight loss was sustained through week 42 with participants achieving up to 10.7% mean weight loss from baseline using the efficacy estimand, compared to 1.7% with placebo. In the cohort that achieved the greatest reduction in body weight, 98% of trial participants treated with petrelintide reached the maintenance dose underscoring its favorable tolerability profile. Accordingly, body weight reduction using the treatme...